Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. - Test2 - elhamkhani - TriplyDB

Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.

Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.

http://www.wikidata.org/entity/Q37403160

about

Undiagnosed MODY: Time for Action Precision diabetes: learning from monogenic diabetes.Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing.What Is the Best NGS Enrichment Method for the Molecular Diagnosis of Monogenic Diabetes and Obesity?Lower Frequency of HLA-DRB1 Type 1 Diabetes Risk Alleles in Pediatric Patients with MODY.Adolescent non-adherence reveals a genetic cause for diabetes Phenotypic heterogeneity in monogenic diabetes: the clinical and diagnostic utility of a gene panel-based next-generation sequencing approach Metabolic disruption in context: Clinical avenues for synergistic perturbations in energy homeostasis by endocrine disrupting chemicals Characteristics of maturity onset diabetes of the young in a large diabetes center.Monogenic diabetes: Implementation of translational genomic research towards precision medicine.GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.Genomic screening for monogenic forms of diabetes.Can Biomarkers Help Target Maturity-Onset Diabetes of the Young Genetic Testing in Antibody-Negative Diabetes?Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial.The diagnosis and management of monogenic diabetes in children and adolescents

P2860

Q28083025-C73644D6-8C9A-40EE-8699-EE53A27D97DD Q33453490-F52317EA-D0F7-43A3-8B3A-51460DDFA982 Q35209499-2AC6B894-2939-4ED6-937E-01ACEAB8C5EA Q35850123-51384A1A-A078-4A67-B615-872C71FF718D Q36239494-4094E716-A8DA-4FF0-8817-9B4C4550E2FA Q36268347-B01B59B2-813D-47C3-8611-562A093C06E8 Q36588444-7E24BAF4-D42B-4B58-8B17-CD00B29BF3EA Q36710350-23C25B79-751C-4E6C-97CC-86F7FC1661F1 Q37068285-B37ED639-4B9D-45A9-A808-61EF16EB430F Q38844084-C2E64D70-40AF-4613-A23B-125ECBC7AE62 Q39828890-9B404697-FF95-4C70-8FFF-6200325ECEB7 Q49843750-54621628-BBBB-4DDC-9BFA-4AA5C10F223C Q49885981-E45C693E-C0B1-47E0-91CD-E1815192A224 Q55032846-413DD2CE-B8C8-4CCB-A9CB-78FF43E2A447 Q57303417-64E7CF90-541B-4A05-BE10-3225DEC4CBC1

P2860

Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications.

http://www.wikidata.org/entity/Q37403160

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-effectiveness of MODY gen ...... practical health applications.

@en

Cost-effectiveness of MODY gen ...... practical health applications.

@nl

type

label

Cost-effectiveness of MODY gen ...... practical health applications.

@en

Cost-effectiveness of MODY gen ...... practical health applications.

@nl

prefLabel

Cost-effectiveness of MODY gen ...... practical health applications.

@en

Cost-effectiveness of MODY gen ...... practical health applications.

@nl

P1433

Q37403160-FB82FE85-C9CA-4071-8BC9-B256B501BD54

P1476

Q37403160-AD5A2535-F898-4DFE-87DD-15BB75F7CDC5

P2093

Q37403160-0B0449F4-E75F-4350-A331-79413559B741

Q37403160-42D158E2-C241-415F-9C91-96A8B29BEBE4

Q37403160-4305094A-6D83-46F4-8EE5-45D6021BD951

Q37403160-51A3DFF4-F106-4C2D-AA5C-CDA9BA2DCA6E

Q37403160-54F685BA-9359-4999-80F4-C8DAA8E48044

Q37403160-82FCD475-4C02-4591-84A6-6DF555F95EA3

Q37403160-94090E19-3D46-47ED-AAE3-6544607B74F1

P2860

Q37403160-023E4E62-D66C-487D-BE00-3F40F69CE72A

Q37403160-15B4AE94-035F-496D-A900-2F9895325423

Q37403160-2C738F26-C3E2-47BD-AB5B-EFBBDE6D193E

Q37403160-2CEFFFEF-B9A2-47D4-A00F-011FC9935DCE

Q37403160-34E1EE04-44E7-433B-A097-AF3A86784844

Q37403160-3B588AB8-8AB6-4092-B660-D8717EAE1511

Q37403160-49023D1E-EE08-4DF5-AF47-8686FDAF2C13

Q37403160-49B61902-DF81-4927-9279-29EC1AB0CF08

Q37403160-59F0D8D3-0BCB-4B87-BED6-D72B556E5EFA

Q37403160-661F3243-3609-4060-95C4-9E1AF19CA82D

P304

Q37403160-8F77B8EB-48AD-48E4-8D7A-B212AB2E4830

P31

Q37403160-F55762D2-2313-462A-BC09-DF2F637021EB

P356

Q37403160-849FCD52-5B75-4280-A863-3815A1CA9164

P407

Q37403160-B0AB5690-A3EF-4261-888C-508492DD18F9

P433

Q37403160-2DEA988C-D6C3-43B2-8AD8-F6ECCFDCDDD3

P478

Q37403160-305126ED-CA67-4BB2-AF76-2C51E082CEED

P50

Q37403160-6E2DC185-1056-4AE4-B2C0-EFB332F3AA3A

P577

Q37403160-3053C7F9-5B00-49C6-938E-323E4F54119D

P5875

Q37403160-138D2AF6-94E0-4256-938C-DD4509B8C38C

P698

Q37403160-95E6E7A7-79D8-449F-869C-104658491A4F

P932

Q37403160-E7CE8592-3396-4367-8CD2-A765D497823A

P356

P1433

P1476

Cost-effectiveness of MODY gen ...... practical health applications

@en

P2093

Aaron N Winn

http://www.w3.org/2001/XMLSchema#string

Elbert S Huang

http://www.w3.org/2001/XMLSchema#string

Graeme I Bell

http://www.w3.org/2001/XMLSchema#string

Louis H Philipson

http://www.w3.org/2001/XMLSchema#string

Priya M John

http://www.w3.org/2001/XMLSchema#string

Rochelle N Naylor

http://www.w3.org/2001/XMLSchema#string

Siri Atma W Greeley

http://www.w3.org/2001/XMLSchema#string

P2860

Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin

National trends in treatment of type 2 diabetes mellitus, 1994-2007

Genetic cause of hyperglycaemia and response to treatment in diabetes

Obesity as a medical problem

Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus.

beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors.

Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.

A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.

Double heterozygous mutations involving both HNF1A/MODY3 and HNF4A/MODY1 genes: a case report

Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.

P304

202-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0410

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256501314

http://www.w3.org/2001/XMLSchema#string

P698

24026547

http://www.w3.org/2001/XMLSchema#string

P932

3867988

http://www.w3.org/2001/XMLSchema#string